DekaBank Deutsche Girozentrale Purchases 64,613 Shares of Edwards Lifesciences Co. (NYSE:EW)

DekaBank Deutsche Girozentrale increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.8% during the 3rd quarter, Holdings Channel reports. The firm owned 1,747,168 shares of the medical research company’s stock after purchasing an additional 64,613 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Edwards Lifesciences were worth $115,668,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Crewe Advisors LLC bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $28,000. First Community Trust NA bought a new position in Edwards Lifesciences in the 2nd quarter valued at $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $39,000. Versant Capital Management Inc raised its stake in shares of Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares during the period. Finally, HHM Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $55,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft reduced their price objective on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a report on Thursday, July 25th. UBS Group lowered their target price on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Finally, Piper Sandler cut their price target on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research note on Friday. Fifteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Stock Performance

NYSE EW opened at $69.38 on Friday. The company’s 50 day simple moving average is $68.09 and its two-hundred day simple moving average is $78.39. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a market capitalization of $41.79 billion, a PE ratio of 28.55, a P/E/G ratio of 3.00 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter last year, the business posted $0.59 earnings per share. The firm’s revenue was up 8.9% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock valued at $1,099,238 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.